Dear Reader,
There's been no better investment on the planet this past decade than Bitcoin.
Not gold …
Not bonds …
Nothing.
Over the last ten years …
Bitcoin's returns have more than doubled that of gold, real estate and stocks …
A simple $1 investment in Bitcoin when it first traded seventeen years ago …
Would be worth more than $100 million dollars.
That's enough to make your head spin.
It might give you a serious case of FOMO.
But …
Before you rush to move your retirement plan into Bitcoin …
Hoping for these types of gains …
I've got news for you.
It's not going to happen.
Because as we speak …
A seismic shift is reshaping the crypto landscape.
Money is flowing out of Bitcoin …
And into a handful of exceptional cryptos.
Coins that have the potential for their gains to blow past Bitcoin.
And it's all happening at a rapid pace.
Presenting investors with an amazing opportunity.
To find out more about this huge development, click here
Regards,
Chris Hurt, Weiss Ratings
P.S. Juan Villaverde has called every bull and bear market in crypto since 2012.
Including the top and bottom of Bitcoin in 2018 …
To within days.
As a matter of fact …
He's sitting on four different gains of more than 1,100% on Bitcoin.
But now …
He's saying it's time to invest in another crypto.
To find out what it is, click here.
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Written by Chris Markoch. Published 10/8/2025.
Key Points
- Pfizer has rebounded on news of its participation with the TrumpRx platform, but questions remain about margins and the impact of its new pricing agreements.
- AbbVie offers stronger earnings growth potential, a deep late-stage pipeline, and smart onshoring moves to support future demand.
- Johnson & Johnson is emerging from legal headwinds with a leaner business model, attractive valuation, and a long dividend growth streak.
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its Sept. 25 closing price of about $23.61.
This is welcome news for long-term holders who endured a significant decline after the vaccine-fueled surge in 2021. PFE trades at an attractive multiple of approximately 9x forward earnings and is a steady dividend payer with a dividend yielding 6.4%.
Stopping the Deadliest Animal on Earth (Ad)
Med-X Gearing Up For a Possible NASDAQ Listing (Ticker: MXRX) But the Real Opportunity is Now – Before They Hit the Big Stage
With $6.4M in sales in just four years, expanding to 41 international markets, Med-X is getting ready for the next step... Simpler, Safer, More Effective Pesticides
However, the details matter. Investors should watch for which drugs are included in the program. Pfizer will likely exempt its premium drugs, and with good reason: the program's mechanics may increase volume but at prices that could compress margins.
The bull case for Pfizer remains centered on its pipeline of more than 100 drug candidates, many of which position the company in customizable medicine. That long-term innovation story may be the best reason to own PFE, but two other medical stocks could be more suitable options right now.
AbbVie’s Onshoring Strategy Aligns With U.S. Policy Goals
As of this writing, AbbVie Inc. (NYSE: ABBV) is not part of the TrumpRx platform. That doesn’t mean it isn’t taking steps to limit potential policy risk. The company has announced plans to onshore some manufacturing capacity in the United States, which aligns with the Trump administration’s push to strengthen domestic supply chains for critical industries.
In late September, AbbVie said it would launch its recently approved ovarian cancer drug, Elahere, in the United Kingdom at a list price matching the U.S. price. That move is consistent with the administration’s call for drug makers to offer the U.S. "most-favored-nation" pricing.
Even before that announcement, at least two analysts had set a price target of $251 on ABBV stock, a gain of nearly 10% from its Oct. 6 price. Meanwhile, analysts are forecasting more than 13% earnings growth over the next 12 months, suggesting some price targets could be conservative.
Over the last five years, ABBV has delivered a total return of more than 225%, supported by steady earnings growth and a dividend yield of 2.87%. That performance underscores the strength of AbbVie’s core drugs and its ability to balance income generation with innovation. The company also maintains a deep pipeline, with more than 50 drug candidates in late-stage clinical trials.
Johnson & Johnson’s Streamlined Focus Strengthens Its Pharma Edge
Johnson & Johnson (NYSE: JNJ) offers a different way to play the pharmaceutical sector. After selling its consumer products division in 2023, the streamlined company now operates three divisions, including a pharmaceuticals unit that develops drugs across immunology, oncology, neuroscience, and infectious diseases.
Over the last five years, JNJ stock has returned more than 46%, with much of the recent gain occurring in the past 12 months. The company is now moving beyond a long-running lawsuit related to talc powder and alleged links to ovarian cancer, an overhang that kept many investors on the sidelines. Does the stock’s recent rally mean the catch-up trade is finished?
From a valuation standpoint, not necessarily. Trading at about 17x earnings, JNJ sits at a discount to its historical average. Analysts have been raising price targets ahead of the company’s Oct. 14 earnings report, indicating renewed confidence. With a dividend yield of 2.76% and a 64-year track record of consecutive increases, JNJ offers investors a combination of value, reliability, and steady income.
This email communication is a paid sponsorship for Weiss Ratings, a third-party advertiser of MarketBeat. Why did I get this email content?.
11780 US Highway 1,
Palm Beach Gardens, FL 33408-3080
Would you like to edit your e-mail notification preferences or unsubscribe[/link] from our mailing list?
Copyright © 2025 Weiss Ratings. All rights reserved.
If you have questions or concerns about your account, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
Copyright 2006-2025 MarketBeat Media, LLC.
345 North Reid Place #620, Sioux Falls, South Dakota 57103-7078. United States of America..
Post a Comment
Post a Comment